Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yahui Long Biotechnology Co., Ltd. (referred to as "Yahui Long") for suspected misleading statements related to a strategic cooperation framework agreement disclosed on January 7 [1] Group 1: Investigation and Regulatory Actions - On February 6, Yahui Long received a notice from the CSRC regarding the investigation for violations of information disclosure laws [1] - The company stated that all its business activities are operating normally and it will cooperate with the CSRC during the investigation [1] - The CSRC aims to maintain healthy market development through this investigation [1] Group 2: Strategic Cooperation and Market Response - Yahui Long announced a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd. (referred to as "Brain Machine Starlink") to develop brain-machine interface products [3] - Following the announcement, the Shanghai Stock Exchange (SSE) issued an inquiry letter requesting additional information about the cooperation, including technical routes and product statuses [4] - In response to the SSE's inquiry, Yahui Long clarified that Brain Machine Starlink is a small company with limited commercialization capabilities and that the products are still in early development stages [5] Group 3: Market Performance - On January 6, the stock price of Yahui Long increased by 6.52%, with trading volume rising by 299% compared to the previous trading day [6]

智通财经记者 | 李科文 智通财经编辑 | 谢欣 脑机接口已成上海未来产业重点发展方向。 日前，上海"十五五"规划明确以先进制造业为骨干，构建"2+3+6+6"现代化产业体系，打造世界级高端 产业集群。其中，在六大新兴支柱产业集群，未来健康领域提及加强脑机接口的敏捷布局，加快培育成 势。 2026年上海两会期间，市政协委员、复旦大学附属华山医院神经外科副主任吴劲松建议，当前正处于脑 机接口技术从实验室走向产业化的关键期，上海必须把握机遇，加快打造世界脑机接口中心城市。 非侵入式因操作简便、安全性高，已在消费级及部分医疗场景中应用，但受颅骨阻隔影响，信号采集精 度有限，短期内难以支撑重症患者的高要求康复。侵入式与半侵入式虽然面临技术与伦理挑战，却已成 为医疗康复领域的核心突破方向。 上海市卫生和健康发展研究中心主任金春林向智通财经表示，"未来健康"定位以将脑机接口定义为超越 传统医疗器械范畴，视作生命科学、人工智能与先进制造交叉的前沿方向。战略信号明确，强政策支持 上海抢占全球科技竞争制高点。 他认为，"敏捷布局"的重点在于更灵活、更快速地响应技术迭代与场景拓展，通过机制创新（如快速审 批通道等）加速技术转化， ...

Core Viewpoint - The company YHLO (SH688575) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, following a previous warning from the Shanghai Stock Exchange regarding inaccurate disclosures related to a strategic cooperation agreement [1][3]. Group 1: Regulatory Actions - YHLO received a notice from the CSRC on February 6, indicating that the company is under investigation for alleged violations of the Securities Law and the Administrative Penalty Law of the People's Republic of China [1][3]. - The investigation stems from a January 7 announcement regarding a strategic cooperation framework agreement, which was found to contain misleading statements [1][3]. - The Shanghai Stock Exchange had previously issued a regulatory warning to YHLO's then-Secretary of the Board, highlighting issues of inaccurate and incomplete information disclosure [3][4]. Group 2: Financial Performance - YHLO's 2025 earnings forecast indicates a significant decline, with expected net profit attributable to shareholders dropping over 90% compared to the previous year, projecting between 20 million to 30 million yuan, down from approximately 300 million yuan in 2024 [5][6]. - The company attributes the decline in performance to industry policy impacts, resulting in reduced domestic market demand and lower revenue and gross margin [6][7]. - Additionally, YHLO reported losses from its trading financial assets, specifically from its holdings in Cloud Health Group Limited, and plans to recognize impairment losses on various assets [6][7]. Group 3: Business Operations - Despite domestic challenges, YHLO has achieved some success in overseas markets, with stable growth in international marketing and ongoing efforts in product development and market access [7]. - The company has completed the highest level (Class D) IVDR CE certification for its full range of preoperative chemiluminescence testing reagents, indicating progress in its product offerings [7].

Group 1: Company Overview - Chengdu Sailano Medical Technology Co., Ltd. (Sailano) has officially signed to establish its headquarters in Chengdu Tianfu International Bio-City, focusing on the field of structural heart disease [1][3] - Sailano aims to become a unicorn in the field of pan-cardiac disease medical devices, with a global innovation capability and a forward-looking vision [3] - The company holds 21 invention patents and 19 utility model patents, showcasing its strong intellectual property portfolio [3] Group 2: Research and Development - Sailano plans to build a headquarters, R&D center, and production base in the bio-city to systematically conduct research, production, and sales of medical devices for structural heart disease [3] - The company has established close clinical trial cooperation with top cardiac centers in China, creating a collaborative innovation system from clinical needs to technology transfer [3] - Sailano's product pipeline targets the core area of interventional treatment for structural heart disease, with several in-development products possessing "international advanced" technical advantages [3] Group 3: Clinical Applications and Collaborations - The company will leverage its existing clinical cooperation network and R&D platform to accelerate clinical research, registration, and industrialization of core products after settling in the bio-city [3] - The high-frequency skin ultrasound technology developed by Tianfu Jin Cheng Laboratory has entered clinical validation, providing a new tool for skin disease diagnosis and treatment evaluation [6][10] - The technology aims to enhance the precision of skin disease diagnosis by offering non-invasive, real-time imaging capabilities [10] Group 4: Industry Developments - Chengdu Biomedicine has seen multiple advancements in various subfields, including the structural heart disease sector [4] - Chengdu Baili Tianheng Pharmaceutical Co., Ltd. has been recognized in the "2025 Hurun China 500" list, ranking 86th with a value of 153 billion yuan, an increase of 79.5 billion yuan [12] - Baili Tianheng is developing innovative drugs in the tumor macromolecule treatment field and has received multiple breakthrough therapy designations from regulatory agencies [12]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yahui Long Biotechnology Co., Ltd. for allegedly misleading statements in their announcements regarding a strategic cooperation framework agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. [1] Group 1: Company Actions and Announcements - On January 6, Yahui Long announced a strategic cooperation agreement with Brain Machine Star Chain, claiming collaboration in product development, market promotion, and equity investment, highlighting the latter's focus on artificial intelligence and various technology paths [1] - Following regulatory pressure, Yahui Long issued a supplementary announcement clarifying that Brain Machine Star Chain's current research products only involve non-invasive technology and that some products are still in early research or preclinical stages [1] Group 2: Regulatory Responses - On January 7, the Shanghai Stock Exchange issued a regulatory warning to Yahui Long and related responsible parties, emphasizing the need for accurate and complete information disclosure, especially regarding the hot market concept of "brain-machine interfaces" [2] - The announcement from Yahui Long contained inconsistent statements about the technology paths of Brain Machine Star Chain and failed to adequately address key investor concerns regarding cooperation feasibility and associated risks [2] Group 3: Industry Context - Multiple listed companies have faced regulatory warnings and investigations this year for allegedly misleading statements related to market trends, including Ningbo Rongbai New Energy Technology Co., Ltd. and Ningbo Tianpu Rubber Technology Co., Ltd., indicating a broader trend of scrutiny in the industry [3] - The regulatory environment is tightening as the exchanges have taken action against several companies for "hitching a ride" on market hotspots, highlighting the importance of accurate disclosures in maintaining market integrity [3]

● 本报记者昝秀丽 证监会2月6日消息，1月7日，深圳市亚辉龙生物科技股份有限公司披露签署战略合作框架协议的公告， 涉嫌误导性陈述。近日，证监会已对亚辉龙立案调查。证监会表示，下一步，将在全面调查的基础上依 法处理，切实维护市场健康发展。 上交所于1月7日发布关于对深圳市亚辉龙生物科技股份有限公司及有关责任人予以监管警示的决定。 经查明，公司于1月6日收盘后披露《关于自愿披露签署战略合作框架协议的公告》称，公司与深圳脑机 星链科技有限公司签订《战略合作框架协议》，双方将在产品研发、市场推广以及股权投资等方面开展 合作，并称脑机星链是一家以人工智能为核心驱动力，深耕非侵入式与侵入式双技术路径的企业，已开 发脑电采集分析仪等产品。该公告披露后，引发媒体报道及市场关注。经上交所督促，公司于当晚又发 布《关于自愿披露签署战略合作框架协议的补充公告》称，脑机星链目前在研产品的技术路线为非侵入 式技术路径，尚无侵入式技术布局，且脑电采集分析仪等产品尚未进入注册申报阶段，有的产品尚处于 早期研发阶段或临床前阶段。 当前"脑机接口"为市场热点概念，为投资者高度关注。特别是，公司股价当日(1月6日)收盘上涨 6.52%、成交量 ...

Group 1 - Two companies, Yahui Long and Tian Sheng New Materials, are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1][6] - Yahui Long is being investigated for allegedly misleading statements in its announcement regarding a strategic cooperation framework agreement [2][4] - Tian Sheng New Materials is under investigation for potentially failing to disclose related party transactions for the year 2023 [1][6] Group 2 - Yahui Long's announcement about its cooperation with Brain Machine Star Chain included inaccurate and incomplete information, particularly regarding the technical paths of the products involved [2][3][4] - The Shanghai Stock Exchange issued a regulatory warning to Yahui Long and its former board secretary for failing to provide adequate risk disclosures, which led to a significant stock price increase of 6.52% on January 6 [4][5] - Tian Sheng New Materials is currently conducting normal business operations and claims that the investigation will not significantly impact its activities [6]

Group 1 - Two companies, Yahui Long and Tiansheng New Materials, are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1][6] - Yahui Long is being investigated for allegedly misleading statements in its announcement regarding a strategic cooperation framework agreement [2][4] - The CSRC has indicated that Yahui Long's disclosures related to "brain-computer interface" technology were inaccurate and incomplete, lacking sufficient risk warnings [2][4] Group 2 - Tiansheng New Materials announced that its investigation may involve undisclosed related party transactions for the fiscal year 2023 [6] - The company stated that its normal business operations are not expected to be significantly impacted by the investigation [6] - Tiansheng New Materials is known for its production of polymer materials, including soft foam materials and structural foam products [6]

当前,脑机接口在认知领域的角色,更像是"学习加速器"或"状态调节器",有望帮助我们提升专注力、记忆 力或辅助感知,而非替代学习过程本身。 知识并非静态的"文件",而是大脑神经元之间动态、复杂的连接模式。人类尚未破解大脑存储和读取知 识的底层"神经编码",自然无法将外部信息"转译"成大脑能理解的信号。 强行向大脑写入未经验证的信息模式,不仅技术上面临着信号通道带宽不足的物理限制,更可能干扰甚至 破坏原有的神经连接,导致不可预知的后果。 想要实现"知识一键拷贝",还得先破解神经编码、提升设备带宽、解决生物兼容等一系列难题,乐观估计 也需要半个世纪甚至更久。 随着脑机接口的新闻频出,不少人幻想:能否跳过学习过程,像拷贝文件一样,将知识直接输入大脑?这个充 满科幻感的设想,在可预见的未来仍难以实现。 目前,即便最先进的脑机接口(如Neuralink的临床实验),其核心能力仍停留在解读和输出简单的运动意图 信号(如移动光标、点击按钮),远未达到处理复杂逻辑、语言和知识结构的水平。 ...

Core Insights - The article highlights the introduction of the Fuxiaozhi F1-D humanoid robot, which integrates non-invasive brain-computer interface technology to address early intervention challenges for autism in China, potentially benefiting over 13 million patients, especially young children [2][6]. Group 1: Autism Intervention Challenges - Approximately 60% of autistic children show significant symptoms before the age of three, but due to uneven medical resource distribution and public awareness, the average diagnosis age is delayed to 4-5 years, missing the critical intervention window [2]. - Current autism rehabilitation faces several bottlenecks, including reliance on therapists' personal experience, lack of objective quantification standards, and a scarcity of professional rehabilitation resources, with only about 35% of autistic patients aged 0-17 receiving systematic support [2]. Group 2: Fuxiaozhi F1-D Technology - The Fuxiaozhi F1-D features a "mind-reading" capability through a non-invasive, easy-to-wear "smart hat" that captures weak brain signals, which are then interpreted and translated into actions by the robot [3][4]. - The robot can respond to children's emotional states and attention levels, providing engaging feedback during rehabilitation, thus transforming traditional training into a game-like experience [5]. Group 3: Personalized Interaction and Data Utilization - Fuxiaozhi F1-D employs a personalized interaction model, adapting to each child's unique needs, such as adjusting sound levels for sound-sensitive children, thereby addressing the "one-size-fits-all" approach in traditional training [5]. - The system collects and analyzes brainwave, movement, and behavior data, offering unprecedented objective metrics for early screening and rehabilitation effectiveness, moving away from subjective assessments [5]. Group 4: Broader Industry Context - The introduction of Fuxiaozhi F1-D signifies a broader application of brain-computer interface technology in autism rehabilitation across China, with other systems like "Xingbinle" and "Autism Brain-Machine Assisted Diagnosis System" also emerging [7]. - The Chinese government's "14th Five-Year Plan" includes brain-computer interfaces as a key growth area, indicating a shift towards integrating advanced technologies in rehabilitation practices [7]. Group 5: Future Prospects - Future iterations of Fuxiaozhi may incorporate more advanced features, such as multi-sensory positive reinforcement and early risk warning systems, potentially shifting the focus from treatment to prevention [9][10]. - The integration of brain-computer interfaces with AI and big data technologies is expected to lead to more innovations like Fuxiaozhi, helping autistic children find their place in society [10].